Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741754 | 0.81 | L3MBTL1 (0.49) | BRD4L3MBTL1ALDH1A1TSHRMEN1 | |
| SCHEMBL21159622 | 0.76 | BRD4 (0.61) | BRD4L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL11437380 | 0.76 | MEN1 (0.50) | BRD4L3MBTL1ALDH1A1TSHRMEN1 | |
| Trifluoroacetic Acid SCHEMBL3267697 | 0.76 | BRD4 (0.44) | BRD4L3MBTL1ALDH1A1TSHRMEN1 | |
| SCHEMBL3411031 | 0.75 | APP (0.43) | BRD4FFAR1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL4133614 | 0.74 | ALDH1A1 (0.49) | BRD4L3MBTL1ALDH1A1TSHRMEN1 | |
| SCHEMBL8314901 | 0.73 | SMN1; SMN2 (0.60) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23250797 | 0.73 | L3MBTL1 (0.49) | BRD4L3MBTL1ALDH1A1TSHRMEN1 | |
| SCHEMBL2514445 | 0.73 | HRH2 (0.53) | — | |
| SCHEMBL8986471 | 0.72 | MAPT (0.58) | ALDH1A1KMT2AGAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170087138-A1 | Therapeutic Uses Of Compounds Having Affinity To The Serotonin Transporter, Serotonin Receptors And Noradrenalin Transporter | H LUNDBECK AS (DK) | 2017-03-30 | — | — | US | disclosed |
| US-20170037006-A1 | CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL] PIPERIDINE | H LUNDBECK AS (DK) | 2017-02-09 | — | — | US | disclosed |
| US-9315459-B2 | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine | H. LUNDBECK A/S (DK) | 2016-04-19 | — | — | US | disclosed |
| US-20150073018-A1 | CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL] PIPERIDINE | LUNDBECK & CO AS H (DK) | 2015-03-12 | — | — | US | disclosed |
| US-20140296290-A1 | THERAPEUTIC USES OF COMPOUNDS HAVING AFFINITY TO THE SEROTONIN TRANSPORTER, SEROTONIN RECEPTORS AND NORADRENALIN TRANSPORTER | LUNDBECK & CO AS H (DK) | 2014-10-02 | — | — | US | disclosed |
| EP-2167085-B1 | 4- [2- (4-METHYLPHENYLSULFANYL) PHENYL]PIPERIDINE FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) | LUNDBECK & CO AS H (DK) | 2013-12-25 | — | — | EP | disclosed |
| US-8507526-B2 | 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (IBS) | H. LUNDBECK A/S (DM) | 2013-08-13 | — | — | US | disclosed |
| US-20130190352-A1 | CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN | H. LUNDBECK A/S (DK) | 2013-07-25 | — | — | US | disclosed |
| EP-2139479-B1 | 4-[2-(4-METHYLPHENYLSULFANYL)PHENYL]PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF ADHD, MELANCHOLIA, TREATMENT RESISTENT DEPRESSION OR RESIDUAL SYMPTOMS IN DEPRESSION | LUNDBECK & CO AS H (DK) | 2012-12-12 | — | — | EP | disclosed |
| US-8299095-B2 | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition and uses thereof | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | disclosed |
| EP-2167085-A1 | 4- [2- (4-METHYLPHENYLSULFANYL) PHENYL]PIPERIDINE FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) | H. Lundbeck A/S (DK) | 2010-03-31 | — | — | EP | disclosed |
| EP-2139479-A2 | 4-[2-(4-METHYLPHENYLSULFANYL)PHENYL]PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF ADHD, MELANCHOLIA, TREATMENT RESISTENT DEPRESSION OR RESIDUAL SYMPTOMS IN DEPRESSION | H. Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2129377-A1 | LIQUID FORMULATIONS OF SALTS OF 4-[2-(4-METHYLPHENYLSULFANYL)PHENYL]PIPERIDINE | H.Lundbeck A/S (DK) | 2009-12-09 | — | — | EP | disclosed |
| US-20090264465-A1 | CRYSTALLINE FORMS OF 4- [2- (4-METHYLPHENYLSULFANYL) -PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN | H. LUNDBECK A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| WO-2009076962-A1 | THERAPEUTIC USES OF COMPOUNDS HAVING AFFINITY TO THE SEROTONIN TRANSPORTER, SEROTONIN RECEPTORS AND NORADRENALIN TRANSPORTER | H. LUNDBECK A/S (DK) | 2009-06-25 | — | — | WO | disclosed |
| EP-2044020-A1 | CRYSTALLINE FORMS OF 4- [2- (4-METHYLPHENYLSULFANYL) -PHENYL]PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN | H.Lundbeck A/S (DK) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008151632-A1 | 4- [2- (4-METHYLPHENYLSULFANYL) PHENYL] PIPERIDINE FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) | H.LUNDBECK A/S (DK) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008113358-A1 | LIQUID FORMULATIONS OF SALTS OF 4-[2-(4-METHYLPHENYLSULFANYL)PHENYL]PIPERIDINE | H. LUNDBECK A/S (DK) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113360-A2 | 4- [2- (4-METHYLPHENYLSULFANYD-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF ADHD, MELANCHOLIA, TREATMENT RESISTENT DEPRESSION OR RESIDUAL SYMPTOMS IN DEPRESSION | H. LUNDBECK A/S (DK) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007144006-A1 | CRYSTALLINE FORMS OF 4- [2- (4-METHYLPHENYLSULFANYL) -PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN | H. LUNDBECK A/S (DK) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264465-A1 | CRYSTALLINE FORMS OF 4- [2- (4-METHYLPHENYLSULFANYL) -PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN | SLC6A4, SLC6A2, SLC18A1 | BRD4 4541/4885FFAR1 1175/4885CCR6 3432/4885 |
| US-20140296290-A1 | THERAPEUTIC USES OF COMPOUNDS HAVING AFFINITY TO THE SEROTONIN TRANSPORTER, SEROTONIN RECEPTORS AND NORADRENALIN TRANSPORTER | SLC6A2, SLC6A4, SLC18A2 | BRD4 3139/4885FFAR1 1251/4885CCR6 2699/4885 |
| US-20150073018-A1 | CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL] PIPERIDINE | PMP22, SCN4A, SFPQ | BRD4 2510/4885FFAR1 2172/4885CCR6 2380/4885 |
| US-20170087138-A1 | Therapeutic Uses Of Compounds Having Affinity To The Serotonin Transporter, Serotonin Receptors And Noradrenalin Transporter | SLC6A2, SLC6A4, SLC18A2 | BRD4 2847/4885FFAR1 1093/4885CCR6 2620/4885 |
| US-20170037006-A1 | CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL] PIPERIDINE | PMP22, SCN4A, SFPQ | BRD4 2510/4885FFAR1 2172/4885CCR6 2380/4885 |
| US-20130190352-A1 | CRYSTALLINE FORMS OF 4-[2-(4-METHYLPHENYLSULFANYL)-PHENYL] PIPERIDINE WITH COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITION FOR THE TREATMENT OF NEUROPATHIC PAIN | SLC6A4, SLC6A2, SLC18A1 | BRD4 4541/4885FFAR1 1175/4885CCR6 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.